JP2024534880A - 抗トランスフェリン受容体抗体及びその使用 - Google Patents

抗トランスフェリン受容体抗体及びその使用 Download PDF

Info

Publication number
JP2024534880A
JP2024534880A JP2024513785A JP2024513785A JP2024534880A JP 2024534880 A JP2024534880 A JP 2024534880A JP 2024513785 A JP2024513785 A JP 2024513785A JP 2024513785 A JP2024513785 A JP 2024513785A JP 2024534880 A JP2024534880 A JP 2024534880A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
tfr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534880A5 (enExample
Inventor
アイシン ダルキリッチ－リドル，
ベンジャミン エー． スミス，
カール ジェイ． エム． ハンフ，
ファン チャン，
アール． ブレイク ペピンスキー，
トーマス オー． キャメロン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2024534880A publication Critical patent/JP2024534880A/ja
Publication of JP2024534880A5 publication Critical patent/JP2024534880A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024513785A 2021-09-01 2022-08-31 抗トランスフェリン受容体抗体及びその使用 Pending JP2024534880A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163239630P 2021-09-01 2021-09-01
US63/239,630 2021-09-01
US202263388088P 2022-07-11 2022-07-11
US63/388,088 2022-07-11
PCT/US2022/042196 WO2023034409A1 (en) 2021-09-01 2022-08-31 Anti-transferrin receptor antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024534880A true JP2024534880A (ja) 2024-09-26
JP2024534880A5 JP2024534880A5 (enExample) 2025-08-22

Family

ID=83508506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513785A Pending JP2024534880A (ja) 2021-09-01 2022-08-31 抗トランスフェリン受容体抗体及びその使用

Country Status (15)

Country Link
US (2) US11827702B2 (enExample)
EP (1) EP4396231A1 (enExample)
JP (1) JP2024534880A (enExample)
KR (1) KR20240107202A (enExample)
AU (1) AU2022340568A1 (enExample)
CA (1) CA3230796A1 (enExample)
CL (1) CL2024000642A1 (enExample)
CO (1) CO2024003577A2 (enExample)
CR (1) CR20240139A (enExample)
IL (1) IL311175A (enExample)
JO (1) JOP20240042A1 (enExample)
MX (1) MX2024002753A (enExample)
PE (1) PE20240895A1 (enExample)
TW (1) TW202328187A (enExample)
WO (1) WO2023034409A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024187057A2 (en) 2023-03-08 2024-09-12 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
CN116735864B (zh) * 2023-08-15 2023-11-10 迦进生物医药(上海)有限公司 评估TfR1抗体血液安全性的试剂盒
IL327952A (en) * 2023-10-26 2026-06-01 Biogen Ma Inc Anti-transferrin receptor antibodies and uses thereof
CN121517563A (zh) * 2024-08-09 2026-02-13 东北制药集团股份有限公司 人源化的靶向TfR1的抗体及其应用
WO2026076250A1 (en) * 2024-10-03 2026-04-09 Genentech, Inc. Lipid nanoparticles for delivery to the cns from systemic administration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015098989A1 (ja) * 2013-12-25 2017-03-23 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
US20170348416A1 (en) * 2014-11-14 2017-12-07 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
WO2021154477A1 (en) * 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
ATE154245T1 (de) 1990-03-27 1997-06-15 Salk Inst For Biological Studi Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen
US5648469A (en) 1992-04-20 1997-07-15 The Salk Institute For Biological Studies Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
JP4756032B2 (ja) 2004-03-31 2011-08-24 アトナーゲン アクチエンゲゼルシャフト 胎児赤血球細胞に対して特異性を有するモノクローナル抗体
WO2005094364A2 (en) 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
EP1740616B1 (en) 2004-04-30 2011-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-tfr antibody.
KR101295139B1 (ko) 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
WO2006096653A2 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
FR2959416B1 (fr) 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
TWI450727B (zh) 2011-12-29 2014-09-01 財團法人工業技術研究院 抗人類輸鐵蛋白受體的單域抗體與其應用
TW201333040A (zh) 2012-01-06 2013-08-16 Bioalliance Cv 抗－輸鐵蛋白受器之抗體及其使用方法
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
DK2918603T3 (en) 2012-11-08 2018-10-15 Univ Miyazaki ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR
WO2014144060A1 (en) 2013-03-15 2014-09-18 Alper Biotech, Llc Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
PL3092251T3 (pl) 2014-01-06 2021-08-02 F. Hoffmann-La Roche Ag Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
IL257065B (en) 2015-07-22 2022-07-01 Inatherys Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
DK3473270T5 (da) 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
US20190375819A1 (en) 2016-10-29 2019-12-12 Rhode Island Hospital Glycosylated transferrin receptor 1 tumor antigen
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
CA3053381A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
WO2019032955A1 (en) 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
CN118638787A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
CN111683972A (zh) 2018-02-05 2020-09-18 Jcr制药股份有限公司 用于将药剂递送至肌肉的方法
CA3108328A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva
CN112930193A (zh) 2018-08-02 2021-06-08 达因疗法公司 肌肉靶向复合物及其在治疗肌肉萎缩中的用途
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830127A4 (en) 2018-08-02 2022-06-29 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating pompe disease
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
EP3829594A4 (en) 2018-08-02 2022-05-11 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
US20210322562A1 (en) 2018-08-02 2021-10-21 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating centronuclear myopathy
AU2019315593B2 (en) 2018-08-02 2026-05-21 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
CA3108386A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating friedreich's ataxia
CN112955154A (zh) 2018-08-02 2021-06-11 达因疗法公司 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
US20240148891A1 (en) 2019-10-18 2024-05-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN115427448A (zh) 2020-01-10 2022-12-02 达因疗法公司 肌肉靶向复合物及其用途
EP4087653A4 (en) 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20230256112A1 (en) 2020-07-23 2023-08-17 Dyne Therapeutics, lnc. Anti-transferrin receptor (tfr) antibody and uses thereof
AU2021414227A1 (en) 2020-12-31 2023-07-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015098989A1 (ja) * 2013-12-25 2017-03-23 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
US20170348416A1 (en) * 2014-11-14 2017-12-07 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
WO2021154477A1 (en) * 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof

Also Published As

Publication number Publication date
TW202328187A (zh) 2023-07-16
CO2024003577A2 (es) 2024-06-27
US20240158494A1 (en) 2024-05-16
MX2024002753A (es) 2024-05-20
WO2023034409A1 (en) 2023-03-09
EP4396231A1 (en) 2024-07-10
US20230131379A1 (en) 2023-04-27
JOP20240042A1 (ar) 2024-02-29
CL2024000642A1 (es) 2024-09-13
CR20240139A (es) 2024-06-14
PE20240895A1 (es) 2024-04-24
KR20240107202A (ko) 2024-07-08
US11827702B2 (en) 2023-11-28
AU2022340568A1 (en) 2024-03-28
CA3230796A1 (en) 2023-03-09
IL311175A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
US11827702B2 (en) Anti-transferrin receptor antibodies and uses thereof
CN111683970B (zh) C-kit结合剂
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
KR101824512B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
CN106459216A (zh) 多特异性抗体构建体
CN118215682A (zh) 抗转铁蛋白受体抗体及其用途
JP7641667B2 (ja) 抗スクレロスチン構築体及びその使用
US12630616B2 (en) Complement C2 binding proteins and uses thereof
KR20250120344A (ko) 트랜스페린 수용체 결합 단백질
CA2986066A1 (en) Multi-specific binding proteins
US12448441B2 (en) ZIP12 antibody
TW202607017A (zh) 抗血清白蛋白之抗原結合蛋白及其用途
AU2023272924A1 (en) Klrb1 binding agents and methods of use thereof
JP2025503707A (ja) ガレクチン－１０抗体
HK40129286A (en) Anti-cd122 antibodies and uses thereof
WO2026091090A1 (zh) 结合april的抗体及其用途
WO2026017189A2 (zh) 抗il-31抗体、其药物组合物及用途
WO2025207959A1 (en) Anti-transferrin receptor antibodies and uses thereof
CN118139882A (zh) 骨骼肌肉系统疾病的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260615

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260615